Pediatric Preclinical Testing Program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237

被引：0
|
作者：
Smith, M. A. [2 ]
Houghton, P. J. [1 ]
Morton, C. L. [1 ]
Maris, J. M. [3 ]
Courtright, J. [3 ]
Carol, H. [4 ]
Lock, R. B. [4 ]
Yang, Y.
Manfredi, M. G.
机构：
[1] St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA
[2] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[4] Childrens Canc Inst Australia, Leukaemia Biol Program, Randwick, NSW, Australia
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72220-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：92 / 93
页数：2
相关论文
共 50 条
  • [31] A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
    Rosenthal, Allison
    Kumar, Shaji
    Hofmeister, Craig
    Laubach, Jacob
    Vij, Ravi
    Dueck, Amylou
    Gano, Katherine
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (02) : 323 - 325
  • [32] c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer
    Li, Yiqi
    Li, Xinru
    Pu, Jun
    Yang, Qi
    Guan, Haixia
    Ji, Meiju
    Shi, Bingyin
    Chen, Mingwei
    Hou, Peng
    THYROID, 2018, 28 (12) : 1642 - 1654
  • [33] A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis
    Gangat, Naseema
    Swords, Ronan T.
    Stein, Brady Lee
    Marinaccio, Christian
    Watts, Justin M.
    Frankfurt, Olga
    Altman, Jessica K.
    Al-Kali, Aref
    Zblewski, Darci
    Gurbuxani, Sandeep
    Wen, Jeremy Q.
    Tapia, Roberto
    Barath, Stephanie
    Graf, Amy
    Handlogten, Amy
    Dinh, Yvonne Trang
    Englund, Kristen
    Patel, Shradha
    Bodes, Orlando
    Ogden, Jillian
    Giles, Francis J.
    Tefferi, Ayalew
    Crispino, John D.
    BLOOD, 2017, 130
  • [34] Pediatric preclinical testing program (PPTP) evaluation of the VEGFR-2 inhibitor AZD2171
    Smith, M. A.
    Maris, J. M.
    Keir, S. T.
    Lock, R. B.
    Gorlick, R.
    Kolb, E. A.
    Keshelava, N.
    Reynolds, C. P.
    Morton, C.
    Houghton, P. J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 34 - 35
  • [35] Pediatric Preclinical Testing Program (PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK) inhibitor
    Smith, Malcolm
    Keir, Stephen
    Maris, John
    Kolb, Anders
    Reynolds, Patrick
    Kang, Min
    Carol, Hernan
    Lock, Richard
    Gorlick, Richard
    Kurmasheva, Raushan
    Billups, Catherine
    Houghton, Peter
    CANCER RESEARCH, 2012, 72
  • [36] Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program
    Keir, Stephen T.
    Morton, Christopher L.
    Wu, Jianrong
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (03) : 586 - 588
  • [37] The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine
    Kelly, Kevin R.
    Swords, Ronan T.
    Mahalingam, Devalingam
    Nawrocki, Steffan T.
    Medina, Ernest
    Smith, Sabrina
    Padmanabhan, Swaminathan
    Ecsedy, Jeffrey
    Cahill, Mary R.
    Giles, Francis J.
    Carew, Jennifer S.
    BLOOD, 2009, 114 (22) : 824 - 824
  • [38] Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors
    Falchook, Gerald S.
    Venkatakrishnan, Karthik
    Sarantopoulos, John
    Kurzrock, Razelle
    Mita, Alain C.
    Fu, Siqing
    Mita, Monica M.
    Zhou, Xiaofei
    Jung, Jung Ah
    Ullmann, Claudio Dansky
    Milch, Catherine
    Rosen, Lee S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (07) : 563 - 572
  • [39] Anti-Tumor Activity of the Aurora a Inhibitor MLN8237 in Diffuse Large B-Cell Lymphoma Preclinical Models
    Huck, Jessica J.
    Zhang, Mengkun
    Hyer, Marc L.
    Manfredi, Mark G.
    BLOOD, 2008, 112 (11) : 565 - 565
  • [40] FOOD EFFECT STUDY OF THE INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) IN PATIENTS WITH ADVANCED SOLID TUMORS
    Falchook, G. S.
    Zhou, X.
    Rosen, L. S.
    Venkatakrishnan, K.
    Kurzrock, R.
    Mahalingam, D.
    Goldman, J.
    Jung, J.
    Milch, C.
    Sarantopoulos, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 168 - 168
12345